Mirimus is an XPRIZE award-winning biotech and preclinical CRO delivering scalable solutions for the preclinical evaluation of novel therapeutic targets through the use of our advanced genetically engineered in vivo models. With cutting-edge gene editing and RNA interference (RNAi) technologies, we are leaders in developing human models of disease.
We are driving advancements in human health by providing high-quality animal and cell models for critical in vivo studies. We empower researchers to gain precise control over in vivo gene expression by designing precise, translatable, genetically-engineered animal and cellular models with potent, reversible gene silencing.
Customize RNAi and CRISPR/Cas9 mouse and rat models with potent, reversible gene silencing for drug discovery and target validation.
Learn More
Recreate the architecture and physiology of human organs with clinically relevant 3D tissue cultures developed from induced pluripotent stem cells (iPSCs).
Learn More
Unlock the therapeutic potential of RNA Interference (RNAi) and accelerate the development of new therapies for the world’s most challenging diseases.
Learn More
